Prostaglandin E1 : electrophysiological safety in patients with congestive heart failure and peripheral arterial occlusive disease. The Alprostadil Investigators.
Prostaglandin E ( 1 ) (PGE ( 1 ) ), the active ingredient of the drug alprostadil-alpha-cyclodextrin, has been effective in mitigating the clinical manifestations of peripheral arterial occlusive disease (PAOD). PGE ( 1 ) often is administered to patients with the potential for developing serious arrhythmias, presenting potential safety hazards if the drug caused or potentiated arrhythmias. However, PGE ( 1 ) has antiadrenergic properties and, theoretically, might have an antiarrhythmic action. Therefore, the effect of PGE ( 1 ) on frequency and severity of atrial and ventricular arrhythmias was evaluated from 48-hour electrocardiographic recordings in patients receiving PGE ( 1 ) therapy for severe PAOD. No significant effects on arrhythmia frequency or severity, and no evidence of proarrhythmia, was apparent after PGE ( 1 ) administration.
Somberg
J C
JC
Department of Medicine, Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL 60064, USA.
Yelamanchi
V
V
Molnar
J
J
Aschermann
M
M
Bernink
P J
PJ
Caspi
A
A
Marmor
A
A
Rabinowitz
B
B
Reisin
L
L
Ruzyllo
W
W
D000527:Alprostadil / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D004311:Double-Blind Method; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*
D000527:Alprostadil